POXEL SA (POXEL.PA)

FR0012432516 - Common Stock

0.462  -0.02 (-4.05%)

Fundamental Rating

1

Taking everything into account, POXEL scores 1 out of 10 in our fundamental rating. POXEL was compared to 82 industry peers in the Biotechnology industry. Both the profitability and financial health of POXEL have multiple concerns. POXEL is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

POXEL had negative earnings in the past year.
In the past year POXEL has reported a negative cash flow from operations.
POXEL had negative earnings in 4 of the past 5 years.
POXEL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

POXEL has a Return On Assets of -345.44%. This is amonst the worse of the industry: POXEL underperforms 92.21% of its industry peers.
Industry RankSector Rank
ROA -345.44%
ROE N/A
ROIC N/A
ROA(3y)-60.88%
ROA(5y)-43.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of POXEL (0.13%) is comparable to the rest of the industry.
POXEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

POXEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
POXEL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, POXEL has more shares outstanding
The debt/assets ratio for POXEL is higher compared to a year ago.

2.2 Solvency

POXEL has an Altman-Z score of -13.49. This is a bad value and indicates that POXEL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.49, POXEL is doing worse than 88.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.49
ROIC/WACCN/A
WACC6.11%

2.3 Liquidity

POXEL has a Current Ratio of 0.77. This is a bad value and indicates that POXEL is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.77, POXEL is doing worse than 89.61% of the companies in the same industry.
POXEL has a Quick Ratio of 0.77. This is a bad value and indicates that POXEL is not financially healthy enough and could expect problems in meeting its short term obligations.
POXEL has a Quick ratio of 0.77. This is amonst the worse of the industry: POXEL underperforms 89.61% of its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77

4

3. Growth

3.1 Past

POXEL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.62%.
The Revenue has grown by 650.49% in the past year. This is a very strong growth!
The Revenue for POXEL have been decreasing by -33.77% on average. This is quite bad
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-78.52%
Revenue 1Y (TTM)650.49%
Revenue growth 3Y-70.61%
Revenue growth 5Y-33.77%
Revenue growth Q2Q1050.6%

3.2 Future

Based on estimates for the next years, POXEL will show a very negative growth in Earnings Per Share. The EPS will decrease by -10.87% on average per year.
POXEL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 86.16% yearly.
EPS Next Y35.27%
EPS Next 2Y-1.22%
EPS Next 3Y-4.22%
EPS Next 5Y-10.87%
Revenue Next Year-49.6%
Revenue Next 2Y322.98%
Revenue Next 3Y54.02%
Revenue Next 5Y86.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

POXEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for POXEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

POXEL's earnings are expected to decrease with -4.22% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.22%
EPS Next 3Y-4.22%

0

5. Dividend

5.1 Amount

POXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

POXEL SA

EPA:POXEL (2/22/2024, 5:14:10 PM)

0.462

-0.02 (-4.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap18.33M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -345.44%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 0.13%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y35.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)650.49%
Revenue growth 3Y-70.61%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y